presence of at least 1 measurable lesion according to modified RECIST criteria
Evidence (fluorescence in situ hybridization FISH) of
Her-2 overexpression in tumor tissue:Group A: Her-2 +++, Group B: Her-2 + or ++
EGFR-expressing disease as assessed by immunohistochemistry
Recovered from relevant toxicities from other treatment prior to study entry
You may not be if
Prior treatment with trastuzumab for metastatic breast cancer (adjuvant therapy is allowed)
Prior treatment with cetuximab
Concomitant cytotoxic chemotherapy
Treatment with any investigational agent(s) within 4 weeks prior to study entry
Known allergic/hypersensitivity reaction to any of the components of study treatments
severe dyspnea
Myocardial infarction within 6 months prior to study entry, uncontrolled congestive heart failure; or any current grade 3 or 4 cardio-vascular disorder despite treatment
History of significant neurologic or psychiatric disorders
